AACR.org|

You can help to fund the next generation of cancer researchers.

The FDA’s approval for the immunotherapeutic pembrolizumab
is the first based entirely on a tumor biomarker.

Team up with AACR Runners for Research at the AACR Rock 'n'
Roll Philadelphia Half Marathon to raise funds for research.

The FDA’s recent announcement means pembrolizumab
is now approved for five forms of cancer.

A study found that a decrease in circulating tumor cells with
crizotinib treatment was associated with increased survival.

Join AACR and Jefferson's Sidney Kimmel Cancer Center for a
pro-am scramble golf outing to benefit cancer research.

We've distributed more than $224 million
in cancer research funding since 2001

Our Research

We support all forms of research from basic and translational to clinical and population science on the more than 200 types of cancer.

Our People

The AACR's membership – more than 37,000 strong – features the world's leading cancer researchers and includes 40 Nobel laureates.

Our Impact

Our members have been at the forefront of every major advance in cancer research for the last 110+ years.

Donate

Make an Impact: Give to the AACR Foundation, where 88 cents of every dollar we raise supports innovative cancer research.

Donate

Volunteer

Use Your Talents: Help to raise money for cancer research by participating in our events or by creating an event of your own.

Volunteer

Take Action

Raise Your Hand: Get involved with the AACR's efforts to support, advocate for, and communicate the importance of cancer research.

Take Action

You can help to fund the next generation of cancer researchers.

The FDA’s approval for the immunotherapeutic pembrolizumab
is the first based entirely on a tumor biomarker.

Team up with AACR Runners for Research at the AACR Rock 'n'
Roll Philadelphia Half Marathon to raise funds for research.

The FDA’s recent announcement means pembrolizumab
is now approved for five forms of cancer.

A study found that a decrease in circulating tumor cells with
crizotinib treatment was associated with increased survival.

Join AACR and Jefferson's Sidney Kimmel Cancer Center for a
pro-am scramble golf outing to benefit cancer research.

We've distributed more than $224 million
in cancer research funding since 2001

Our Research

Our People

Our Impact

Donate

Volunteer

Take Action

Cancer Connections

Tell Your Cancer Story

Revolutions for Research

Walt Disney World® Marathon Weekend

Cancer Today: Practical Knowledge. Real Hope.

AACR Rock 'n' Roll Philadelphia 1/2 Marathon

2018 Disney Princess Half-Marathon Weekend

2017 Super Run Series

Cancer Research Catalyst

Air Pollution May be Associated With Many Kinds of Cancer

Santa Rosa Marathon

Cancer Survivor Journeys

You can help to fund the next generation of cancer researchers.

The FDA’s approval for the immunotherapeutic pembrolizumab is the first based entirely on a tumor biomarker.

Team up with AACR Runners for Research at the AACR Rock 'n' Roll Philadelphia Half Marathon to raise funds for research.

The FDA’s recent announcement means pembrolizumab is now approved for five forms of cancer.

A study found that a decrease in circulating tumor cells with crizotinib treatment was associated with increased survival.

Join AACR and Jefferson's Sidney Kimmel Cancer Center for a pro-am scramble golf outing to benefit cancer research.

We've distributed more than $224 million in cancer research funding since 2001

Our Research

Our People

Our Impact

Donate

Volunteer

Take Action

Cancer Connections

The FDA’s approval for the immunotherapeutic pembrolizumab
is the first based entirely on a tumor biomarker.

Team up with AACR Runners for Research at the AACR Rock 'n'
Roll Philadelphia Half Marathon to raise funds for research.

The FDA’s recent announcement means pembrolizumab
is now approved for five forms of cancer.

A study found that a decrease in circulating tumor cells with
crizotinib treatment was associated with increased survival.

Join AACR and Jefferson's Sidney Kimmel Cancer Center for a
pro-am scramble golf outing to benefit cancer research.

We've distributed more than $224 million
in cancer research funding since 2001